$34.84
0.37% yesterday
Nasdaq, Jul 15, 10:00 pm CET
ISIN
US4131971040
Symbol
HRMY

Harmony Biosciences Holdings Stock price

$34.84
+1.94 5.90% 1M
-2.09 5.66% 6M
+0.43 1.25% YTD
+0.83 2.44% 1Y
-18.81 35.06% 3Y
-2.17 5.86% 5Y
-2.17 5.86% 10Y
-2.17 5.86% 20Y
Nasdaq, Closing price Tue, Jul 15 2025
+0.13 0.37%
ISIN
US4131971040
Symbol
HRMY
Sector
Industry

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$1.7b
Net debt
positive
Cash
$507.0m
Shares outstanding
57.0m
Valuation (TTM | estimate)
P/E
13.4 | 10.3
P/S
2.7 | 2.3
EV/Sales
2.2 | 1.9
EV/FCF
7.5
P/B
2.8
Financial Health
Equity Ratio
66.0%
Return on Equity
22.0%
ROCE
22.1%
ROIC
29.3%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$744.9m | $860.0m
EBITDA
$218.8m | $310.2m
EBIT
$195.0m | $262.6m
Net Income
$153.0m | $192.0m
Free Cash Flow
$221.7m
Growth (TTM | estimate)
Revenue
20.6% | 20.3%
EBITDA
9.6% | 44.3%
EBIT
0.6% | 37.5%
Net Income
11.3% | 32.4%
Free Cash Flow
6.9%
Margin (TTM | estimate)
Gross
78.3%
EBITDA
29.4% | 36.1%
EBIT
26.2%
Net
20.5% | 22.3%
Free Cash Flow
29.8%
More
EPS
$2.6
FCF per Share
$3.9
Short interest
14.2%
Employees
268
Rev per Employee
$2.7m
Show more

Is Harmony Biosciences Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Harmony Biosciences Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Harmony Biosciences Holdings forecast:

13x Buy
87%
1x Hold
7%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Harmony Biosciences Holdings forecast:

Buy
87%
Hold
7%
Sell
7%

Financial data from Harmony Biosciences Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
745 745
21% 21%
100%
- Direct Costs 161 161
26% 26%
22%
584 584
19% 19%
78%
- Selling and Administrative Expenses 207 207
6% 6%
28%
- Research and Development Expense 141 141
66% 66%
19%
219 219
10% 10%
29%
- Depreciation and Amortization 24 24
300% 300%
3%
EBIT (Operating Income) EBIT 195 195
1% 1%
26%
Net Profit 153 153
11% 11%
21%

In millions USD.

Don't miss a Thing! We will send you all news about Harmony Biosciences Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harmony Biosciences Holdings Stock News

Neutral
Business Wire
about 18 hours ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, July 17, 2025, at 10:00 a.m. ET. To register in advance, please use this link. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences webs...
Neutral
Business Wire
about one month ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational, highly potent, and potentially best-in-class orexin 2 receptor (OX2R) agonist, which demonstrated significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model ...
Neutral
Business Wire
about one month ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin's Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the Di...
More Harmony Biosciences Holdings News

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jeffrey Dayno
Employees 268
Founded 2017
Website www.harmonybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today